Loading
A phase 2 trial of Mirvetuximab soravtansine, Carboplatin in ovarian cancer, run by AbbVie, active and no longer recruiting.
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer is a phase 2 interventional study registered as NCT05456685 by AbbVie, with 125 participants enrolled, started 2022-09-28 and due to reach its primary completion in 2026-11. Interventions recorded: Mirvetuximab soravtansine, Carboplatin. Conditions listed: High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Platinum agents, Carboplatin.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Antibody-drug conjugate (ADC).
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Platinum agents, Carboplatin, Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/